Joos L, Docx L, Schmaal L, Sabbe B G C, Dom G
PC Broeders Alexianen, Boechout, Collaborative Antwerp Psychiatric Research Institute, Universiteit Antwerpen, Belgium.
Tijdschr Psychiatr. 2010;52(11):763-73.
For more than two decades psychiatrists have known about and have promoted modafinil, a very promising stimulant that boosts wakefulness in cases of narcolepsy and also enhances cognitive functions. At present, however, we must conclude that modafinil is hardly ever used to treat illness other than narcolepsy.
To review current attitudes and practice with regard to the use and efficacy of modafinil in the treatment of psychiatric disorders.
Relevant placebo-controlled studies were retrieved via PubMed (Medline) and Web of Science.
Modafinil is used experimentally to treat ADHD, mood disorders, schizophrenia and substance-dependence. Compared to placebo, modafinil achieves positive but mainly variable results on different clinical and cognitive measures. It achieves results very rapidly, within a week, but over a period of time the results stabilise.
Modafinil is particularly successful in the treatment of ADHD, depression and cocaine-dependency on measures of attention and hyperactivity, fatigue and cocaine-use respectively. There is a need for further placebo-controlled trials with longer follow-up periods and larger sample size in order to ensure the safety of the product and to refine its area of efficacy.
二十多年来，精神科医生一直了解并推广莫达非尼，这是一种非常有前景的兴奋剂，可提高发作性睡病患者的清醒度，还能增强认知功能。然而目前，我们必须得出结论，莫达非尼几乎从未用于治疗发作性睡病以外的疾病。
回顾当前关于莫达非尼在治疗精神疾病中的使用及疗效的态度和实践。
通过PubMed（医学文献数据库）和科学网检索相关的安慰剂对照研究。
莫达非尼被用于治疗多动症、情绪障碍、精神分裂症和物质依赖的试验。与安慰剂相比，莫达非尼在不同的临床和认知指标上取得了积极但主要是可变的结果。它能在一周内迅速取得效果，但一段时间后结果会稳定下来。
莫达非尼在治疗多动症、抑郁症和可卡因依赖方面分别在注意力和多动、疲劳以及可卡因使用指标上特别成功。需要进行进一步的安慰剂对照试验，随访期更长且样本量更大，以确保产品的安全性并明确其疗效范围。
